The clinical effect of dydrogesterone used for ovarian stimulation in normal-ovulatory women:a randomized controlled dose-finding study of 10 mg versus 20 mg

Start Date01 Jan 2025

Sponsor / Collaborator-

CTR20244041

/ CompletedNot Applicable

评估受试制剂地屈孕酮片（规格：10 mg）与参比制剂达芙通®（规格：10 mg）在健康成年受试者餐后状态下的单中心、随机、开放、单剂量、四周期、两序列、完全重复交叉生物等效性研究

[Translation] A single-center, randomized, open-label, single-dose, four-cycle, two-sequence, fully repeated crossover bioequivalence study to evaluate the test preparation Dydrogesterone Tablets (strength: 10 mg) and the reference preparation Daphaston® (strength: 10 mg) in healthy adult subjects in the fed state

主要研究目的：研究餐后状态下单次口服受试制剂地屈孕酮片（规格：10 mg，持证商：河南泰丰生物科技有限公司）与参比制剂地屈孕酮片（达芙通®，规格：10 mg，持证商：Abbott B.V.）在健康成年女性受试者体内的药代动力学，评价餐后状态口服两种制剂的生物等效性。次要研究目的：评估受试制剂地屈孕酮片（规格：10 mg）和参比制剂地屈孕酮片（达芙通®，规格：10 mg）在健康成年女性受试者中的安全性。

[Translation]

The main purpose of the study is to study the pharmacokinetics of the test preparation Dydrogesterone Tablets (Specification: 10 mg, licensee: Henan Taifeng Biotechnology Co., Ltd.) and the reference preparation Dydrogesterone Tablets (Duphaston®, Specification: 10 mg, licensee: Abbott B.V.) in healthy adult female subjects after a single oral administration in the fed state, and to evaluate the bioequivalence of the two preparations after oral administration in the fed state. The secondary purpose of the study is to evaluate the safety of the test preparation Dydrogesterone Tablets (Specification: 10 mg) and the reference preparation Dydrogesterone Tablets (Duphaston®, Specification: 10 mg) in healthy adult female subjects.

Start Date10 Nov 2024

Sponsor / Collaborator

Henan Taifeng Biotechnology Co., Ltd.

CTRI/2024/10/075727

/ Not yet recruitingPhase 4IIT

Comparison between Oral Dydrogesterone and Oral Micronized Progesterone in Threatened Abortion : A randomized controlled trial - NIL

Start Date05 Nov 2024

Sponsor / Collaborator-

100 Clinical Results associated with Dydrogesterone

100 Translational Medicine associated with Dydrogesterone

100 Patents (Medical) associated with Dydrogesterone

1,252

Literatures (Medical) associated with Dydrogesterone

01 Apr 2025·MICROBIAL PATHOGENESIS

Dydrogesterone alleviates periodontitis in perimenopausal women undergoing periodontal therapy by decreasing inflammation and mediating oral microbiota

Article

Author: Cui, Liyun ; Man, Ying ; Niu, Feifei ; Song, Jiajia ; Li, Xiaofei ; Cheng, Cheng ; Zhang, Xinyue

OBJECTIVE:

Dydrogesterone (DG), a synthetic isomer of progesterone, plays a potential regulatory role in the periodontal environment. The aim of this study was to investigate the potential effects of DG on periodontitis under periodontal therapy (PT) and the underlying mechanisms related to oral microbiota.

METHODS:

As a cohort study, perimenopausal women with periodontitis and abnormal uterine bleeding associated with ovulatory dysfunction were screened. A total of 30 women received PT (PT group) and 30 women received PT and oral DG 10 mg twice/day for 10 days/month (PT + DG group). At baseline and 3 months after treatment, pocket probing depth (PPD), bleeding index (BI), bleeding on probing (BOP), plaque index, CRP, IL-6, and TNF-α were measured. Additionally, 16S rDNA sequencing was performed to determine the characteristics of oral microbiota, mainly in terms of abundance, diversity, composition, and community structure.

RESULTS:

Three months after treatment, the levels of PPD, BI, and BOP, as well as the levels of CRP, IL-6, and TNF-α in gingival crevicular fluid were significantly lower in the PT + DG group than those in the PT group. After treatment, a relatively lower microbial abundance, and some differences in microbial composition were revealed between the PT and PT + DG groups. At the genus level, significantly fewer Escherichia-Shigella, Porphyromonas, and Absconditabacteriales (SR1), and more Lactobacillus, Gordonia, Bifidobacterium, and Oribacterium were found in the PT group than in the PT + DG group.

CONCLUSIONS:

DG enhances the effect of PT on inhibiting inflammatory response in women with periodontitis by mediating oral microbiota.

01 Mar 2025·INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS

Efficacy and safety of different progestogens in women with first threatened miscarriage: A network meta‐analysis

Review

Author: He, Wei ; Zhao, Hongqiong ; Xia, Chunyu ; Yang, Zhu

Abstract:

Threatened miscarriage is defined as early vaginal bleeding before 12 weeks of gestational age and can occur in any pregnancy regardless of maternal age, race, comorbidities, lifestyle, or socioeconomic status, and about one‐quarter of threatened miscarriages proceed to complete miscarriage. To assess the relative effectiveness and safety of different progestogens in women with first threatened miscarriage, using a network meta‐analysis. A systematic search was conducted in PubMed, EMBASE, and Cochrane Library databases from inception to April 2023. Randomized controlled trials (RCTs) assessing the effectiveness or safety of placebo or different progestogens for the treatment of threatened miscarriage were eligible for inclusion, including dydrogesterone (oral), progesterone (oral, vaginal, rectal), and 17‐α‐hydroxyprogesterone (intramuscular). A Bayesian network meta‐analysis with Markov chain Monte‐Carlo simulation was performed in this study. A pairwise meta‐analysis was carried out by synthesizing studies that compared the same interventions using a fixed‐effects model. The primary outcome was the percentage of miscarriage (defined as delivery before 24 weeks of gestation) and preterm birth (defined as birth before 37 weeks of gestation), and the secondary outcomes were live birth rate, congenital abnormalities, neonatal outcomes (low birth weight <2500 g), and adverse events. The risk of bias was assessed by using the Cochrane Risk of Bias Tool. In total, 18 RCTs with six different interventions were included. Oral dydrogesterone can reduce the risk of miscarriage compared with both placebo (odds ratio [OR] 0.5, 95% confidence interval [CI] 0.32–0.76) and vaginal progesterone (OR 0.57, 95% CI 0.36–0.89) in women with first threatened miscarriage. In women with first threatened miscarriage, oral progesterone also reduced the risk of miscarriage compared with placebo (OR 0.61, 95% CI 0.39–0.93). However, from the available evidence, there was no statistically significant difference between progestogens and placebo in preterm birth, congenital abnormality, and live birth rate. Oral dydrogesterone was safe and better at reducing miscarriage than vaginal progesterone and placebo for women with first threatened miscarriage, and better at reducing miscarriage compared with placebo for women with threatened miscarriage.

01 Feb 2025·EUROPEAN JOURNAL OF ENDOCRINOLOGY

Association of menopausal hormone therapy with risk of cardiovascular disease in Korean women

Article

Author: Byun, Young Sup ; Kim, Gwang Sil ; Yuk, Jin-Sung ; Yoon, Sang-Hee ; Kim, Dong-Gil ; Han, Gwan Hee ; Kim, Byung Gyu ; Kim, Myoung-Hwan

Abstract:

Objective:

To evaluate the association between various regimens and combinations of menopausal hormone therapy (MHT) and the risk of cardiovascular disease (CVD) in clinical practice.

Design:

This was a population-based cohort study.

Methods:

This population-based cohort study used data from the Health Insurance Review and Assessment Service. The data of women who reported entering menopause at ≥40 years of age with no history of CVD in the national health examination between 2011 and 2014 were extracted. A total of 134 298 pairs were included in the MHT and non-MHT groups after 1:1 propensity score matching. The participants were followed until December, 31, 2020.

Results:

During a median follow-up of 7.9 (IQR 6.9-8.9) years, the incidences of CVD were 146 per 100 000 person/year and 179 per 100 000 person/year for the non-MHT and MHT groups, respectively. After adjusting for covariates, MHT use was associated with an increased CVD risk (hazard ratio [HR], 1.22 [1.14-1.31]) compared with the non-MHT group; the risk was based on an increased risk of stroke and coronary artery revascularization. Tibolone (HR, 1.38, [1.27-1.50]) was associated with increased CVD, but estrogen alone or combined estrogen/progestogen was not. There was no difference in CVD risk, regardless of the type of estrogen agent used. For combined estrogen/progestogen therapy, dydrogesterone was associated with reduced CVD risk.

Conclusions:

There was an increased risk of CVD in MHT users. By regimen, tibolone use was associated with increased risk of CVD, whereas estrogen either alone or in combination with progestogen was not. There was no difference according to the type of estrogen. The type of progestogen seems to modify the results, since dydrogesterone was associated with reduced CVD risk.

News (Medical) associated with Dydrogesterone

04 Jul 2024

·www.pharmaceutical-technology.com

Viatris closes $3.37bn divestitures with OTC deal

Viatris completed the last of its $3.37bn divestitures, signing a deal with Cooper Consumer Health to transfer of its OTC business. Credit: SOPA Images via Getty Images. Viatris announced the finalisation of a transaction to divest its over-the-counter (OTC) business, completing the last step in its previously declared $3.37bn divestitures. The US-headquartered company divested its entire OTC business to Cooper Consumer Health, a European OTC drug manufacturer, on 3 July. In the agreement, Cooper Consumer Health has gained access to two manufacturing plants based in Merignac, France; and Confienza, Italy, and a research and development site in Monza, Italy. In its strategic plan, Viatris retained the rights for its blockbuster generic drugs Viagra (sildenafil) and Dymista (azelastine hydrochloride and fluticasone propionate) alongside certain other OTC therapies. Viatris first spread word of the OTC divestiture in October 2023 declaring definitive agreements to divest other areas of the company. Over the last few months, the nutraceutical company Matrix Pharma Private gained access to Viatris’ active pharmaceutical ingredients division and Spanish pharmaceutical company Insud Pharma acquired Viatris’ women’s health business. The latter deal gave Insud Pharma two manufacturing plants in India. Furthermore, a December 2023 definitive agreement transferred Viatris’ European rights for therapies such as Duphaston (Dydrogesterone) and Femoston (estradiol) to Theramex . The generics company also divested commercialisation rights in some non-core markets that were acquired, when Viatris was formed through the combination of Mylan and UpJohn. As per a 3 July press release, Viatris made the various divestitures to help achieve its “long-term gross leverage target” and “increase shareholder return through share buybacks and dividends”. The generics company also plans to use the money to acquire, develop and commercialise more therapies in the future. Last year, the company generated a total revenue of $15.4bn, reaching a free cash flow of $2.4bn. By 28 January 2024, the company had already completed $250m in share repurchases for this year. See Also: Left in limbo: When pharma halts rare disease research The pathway to preventative health: How pharma can support the NHS Long Term Plan In November 2022, Viatris released a strategic update detailing a two-stage plan for business growth with plans to end Phase I by the end of this year and execute Phase II between 2024 and 2028. In the first phase, the company aimed to complete all planned divestitures, have seven consecutive quarters of strong performance and continue progress on key science programmes among other things. At the January 2024 JP Morgan Healthcare Conference, Viatris announced that it had achieved its goals for Phase I and will be advancing to Phase II, which prioritises the growth of the company’s ophthalmology division and prevention of base business erosion.

AcquisitionPhase 2

03 Jul 2024

·www.prnewswire.com

Viatris Brings to Completion All Previously Announced Divestitures With the Closing of its Over-the-Counter Business Divestiture

Achievement of This Major Milestone Further Simplifies and Strengthens the Company and Positions Viatris to Achieve its Key Priorities and Accelerate Future Growth PITTSBURGH, July 3, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that it has closed the divestiture of its Over-the-Counter (OTC) business to Cooper Consumer Health, a leading European over-the-counter drug manufacturer and distributor, bringing to substantial completion all previously announced divestitures. In October, the Company announced it had entered into agreements to divest substantially all of its OTC business, as well as its Women's Healthcare business, its Active Pharmaceutical Ingredients (API) business in India and commercialization rights in certain non-core markets. The completion of the OTC divestiture, the largest of the divestitures that the Company previously announced, is a major milestone in the execution of the Company's strategic plan to considerably simplify the organization in order to increase focus on areas with the greatest potential to accelerate growth, patient impact and shareholder value. The Company believes it found the right fit and future owners for all these well-performing businesses and has been committed to ensuring a successful transition for colleagues, partners, customers and patients. The Company reiterated that the proceeds from its divestitures and its sector-leading cash flow generation gives it line of sight to achieving its key priorities, including: achieving its long-term gross leverage target, increasing shareholder return through share buybacks and dividends, fueling its base business and, importantly, making disciplined, strategic investments to identify, acquire, develop and commercialize innovative assets that can build off its very strong base business and drive future revenue growth. "Closing the divestiture of our OTC business is a significant milestone in the execution of our strategic plan," said Scott A. Smith, Chief Executive Officer, Viatris. "With all our previously announced divestitures now substantially complete, Viatris is stronger and more streamlined. We look forward to an exciting future in which we continue to build on our very strong base business and add to our innovative product pipeline to drive strong future revenue growth and positively affect even more patients' lives worldwide." Divestitures Summary Viatris divested substantially all of its OTC business to Cooper Consumer Health, a leading European over-the-counter drug manufacturer and distributor. The transaction includes two manufacturing sites located in Merignac, France, and Confienza, Italy, and a Research & Development site in Monza, Italy. The Company is retaining rights for Viagra®, Dymista® and select OTC products in certain markets. The transaction closed on July 3, 2024. Viatris previously announced that it has divested its API business in India to Matrix Pharma Private Limited. The transaction includes three manufacturing sites and an R&D lab in Hyderabad, three manufacturing sites in Vizag and third-party API sales. Viatris is retaining some selective R&D capabilities in API. The transaction closed in June 2024. Viatris previously announced that it has divested its Women's Healthcare business, primarily related to oral and injectable contraceptives, to Insud Pharma, a leading Spanish multinational pharmaceutical company. The transaction includes two manufacturing facilities in India: one in Ahmedabad and one in Sarigam. The transaction closed in March 2024. Separately, in another transaction, Viatris previously announced it has divested its rights to women's healthcare products Duphaston® and Femoston® in certain countries to Theramex HQ UK Limited, a leading global specialty pharmaceutical company dedicated to women's health. The transaction (other than in the U.K., which remains subject to regulatory approval) closed in December 2023. As previously indicated, Viatris' next update with respect to 2024 financial guidance will reflect the impact of the OTC divestiture, including adjustments to exclude the expected performance of the OTC business from the closing date of the transaction through the end of 2024. About Viatris Viatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale, currently supplying high-quality medicines to approximately 1 billion patients around the world annually and touching all of life's moments, from birth to the end of life, acute conditions to chronic diseases. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world's most enduring health challenges, access takes on deep meaning at Viatris. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at viatris.com and investor.viatris.com, and connect with us on LinkedIn, Instagram, YouTube and X (formerly Twitter). Forward-Looking Statements This press release includes statements that constitute "forward-looking statements." These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward looking statements may include statements that achievement of this major milestone further simplifies and strengthens the Company and positions Viatris to achieve its key priorities and accelerate future growth; the completion of the OTC divestiture is a major milestone in the execution of the Company's strategic plan to considerably simplify the organization in order to increase focus on areas with the greatest potential to accelerate growth, patient impact and shareholder value; the Company believes it found the right fit and future owners for all these well-performing businesses and has been committed to ensuring a successful transition for colleagues, partners, customers and patients; the proceeds from its divestitures and its sector-leading cash flow generation gives it line of sight to achieving its key priorities, including: achieving its long-term gross leverage target, increasing shareholder return through share buybacks and dividends, fueling its base business and, importantly, making disciplined, strategic investments to identify, acquire, develop and commercialize innovative assets that can build off its very strong base business and drive future revenue growth; we look forward to an exciting future in which we continue to build on our very strong base business and add to our innovative product pipeline to drive strong future revenue growth and positively affect even more patients' lives worldwide; as previously indicated, Viatris' next update with respect to 2024 financial guidance will reflect the impact of the OTC divestiture, including adjustments to exclude the expected performance of the OTC business from the closing date of the transaction through the end of 2024. Because forward-looking statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: actions and decisions of healthcare and pharmaceutical regulators; changes in healthcare and pharmaceutical laws and regulations in the U.S. and abroad; any regulatory, legal or other impediments to Viatris' ability to bring new products to market, including but not limited to "at-risk" launches; Viatris' or its partners' ability to develop, manufacture, and commercialize products; the scope, timing and outcome of any ongoing legal proceedings, and the impact of any such proceedings; the possibility that Viatris may be unable to realize the intended benefits of, or achieve the intended goals or outlooks with respect to, its strategic initiatives; the possibility that Viatris may be unable to achieve intended or expected benefits, goals, outlooks, synergies, growth opportunities and operating efficiencies in connection with divestitures, acquisitions, other transactions or restructuring programs, within the expected timeframes or at all; goodwill or impairment charges or other losses related to the divestiture or sale of businesses or assets; Viatris' failure to achieve expected or targeted future financial and operating performance and results; the potential impact of public health outbreaks, epidemics and pandemics; any significant breach of data security or data privacy or disruptions to our information technology systems; risks associated with international operations; the ability to protect intellectual property and preserve intellectual property rights; changes in third-party relationships; the effect of any changes in Viatris' or its partners' customer and supplier relationships and customer purchasing patterns; the impacts of competition; changes in the economic and financial conditions of Viatris or its partners; uncertainties and matters beyond the control of management, including general economic conditions, inflation and exchange rates; failure to execute stock repurchases consistent with current expectations; stock price volatility; and the other risks described in Viatris' filings with the Securities and Exchange Commission (SEC). Viatris routinely uses its website as a means of disclosing material information to the public in a broad, non-exclusionary manner for purposes of the SEC's Regulation Fair Disclosure (Reg FD). Viatris undertakes no obligation to update these statements for revisions or changes after the date of this press release other than as required by law. SOURCE Viatris Inc.

Acquisition

10 Oct 2023

·www.biospace.com

Theramex Announces Agreement to Acquire the European Rights to Duphaston® and Femoston® From Viatris, Inc.

LONDON--(BUSINESS WIRE)-- Theramex, a leading global speciality pharmaceutical company dedicated to women’s health, is pleased to announce that it has entered into an agreement to acquire the European rights to Duphaston® and Femoston® from Viatris Inc. Viatris retains the rights for Australia and Japan. The transaction is subject to customary regulatory and anti-trust approvals. “As we continue to strengthen our commitment to women’s health and improve our patients access to high quality treatments, we are excited to acquire new products to expand our Menopause portfolio.” - Rob Stewart, CEO of Theramex. Duphaston® (dydrogesterone) and Femoston® (estradiol/dydrogesterone) may be prescribed in indications related to hormone replacement therapy (HRT). About Theramex Theramex is a leading, global specialty pharmaceutical company dedicated to women and their health. With a broad portfolio of innovative and established brands covering contraception, fertility, menopause and osteoporosis, Theramex supports women at different stages of their lives. Our vision is to be a lifetime partner for women and the healthcare professionals who treat them by providing innovative, effective solutions that care for and support women as they advance through each stage of their lives. To learn more about Theramex, please visit . View source version on businesswire.com: Contacts For further information about Theramex, please contact: Katja Lundell, Senior Director, Global Head of Policy, Pricing and Communications. Email: Katja.Lundell@theramex.com Phone : +44 203 962 5555 THX_HQ_PRESSR_011393 Source: Theramex View this news release online at:

License out/inDrug Approval

100 Deals associated with Dydrogesterone

External Link

KEGG	Wiki	ATC	Drug Bank
D01217	Dydrogesterone	G03DB01	DB00378

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Uterine Hemorrhage	CN	Abbott Healthcare Products BV	31 Dec 2002
Abortion, Habitual	JP	Viatris Pharmaceutical GK	31 Oct 1964
Abortion, Threatened	JP	Viatris Healthcare GK	31 Oct 1964
Amenorrhea	JP	Viatris Pharmaceutical GK	31 Oct 1964
Dysmenorrhea	JP	Viatris Pharmaceutical GK	31 Oct 1964
Infertility	JP	Viatris Pharmaceutical GK	31 Oct 1964
Metrorrhagia	JP	Viatris Pharmaceutical GK	31 Oct 1964
Endometriosis	GB	Solvay SA	01 Jan 1961
Menstruation Disturbances	GB	Solvay SA	01 Jan 1961

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Infertility, Female	Phase 3	AT	Alere, Inc.	01 Aug 2013
Infertility, Female	Phase 3	BE	Alere, Inc.	01 Aug 2013
Infertility, Female	Phase 3	FI	Alere, Inc.	01 Aug 2013
Infertility, Female	Phase 3	DE	Alere, Inc.	01 Aug 2013
Infertility, Female	Phase 3	IL	Alere, Inc.	01 Aug 2013
Infertility, Female	Phase 3	RU	Alere, Inc.	01 Aug 2013
Infertility, Female	Phase 3	ES	Alere, Inc.	01 Aug 2013

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03858049 (CTgov)	Phase 4	Infertility	172	Crinone	dyigvpxjnu(twgirgttsu) = lpjqrnhqpx ihfxgjotkc (vjorqluoxh, etvuahpxsw - sjhyanjrgf) View more	-	12 Mar 2024
NCT04537078 (CTgov)	Phase 3	Infertility, Female	90	Combined Oral Contraceptive+Decapeptyl+Cyclo-Progynova+progesterone+Gonadotropin+Duphaston (the Progestin Primed Double Stimulation Group)	sepqqjcyae(xcxhtilzqu) = whdopdkhpf pxpknjajmt (koqnhqyukn, yinbzeyaqs - jlqdchieab) View more	-	17 Feb 2022
				Combined Oral Contraceptive+Cetrotide Injectable Product+Decapeptyl+Cyclo-Progynova+progesterone+Chorionic Gonadotropin+Gonadotropin (the Flexible GnRh Antagonist)	ypukgfwagr(fthpucgrag) = skshkxhsqu bjyczelbwl (cnmdmthfnk, omsqbgbono - rvbdqjzfgn) View more
NCT03935152 (Pubmed \| BMC Pregnancy Childbirth)	Phase 4	Obstetric Labor, Premature	48	Oral dydrogesterone 10mg	vdcsfdseds(kkheirjumc) = mtzyezxrre icwiswaiav (pdxkfpxtlw )	Negative	28 Jan 2021
				Placebo	vdcsfdseds(kkheirjumc) = gasnqaqdxs icwiswaiav (pdxkfpxtlw )
NCT02491437 (Lotus II, CTgov)	Phase 3	Infertility, Female	1,034	Dydrogesterone 30 mg (Dydrogesterone Tablets 3x10 mg)	gvlzghugku(sskdvlewar) = epnygbivfy uvsclucbgv (wtcxcgjpmn, bqjbwtjixx - einzkuxqus) View more	-	01 Oct 2019
				intravaginal progesterone gel 90 mg (Crinone 8% Intravaginal Progesterone Gel 90 mg)	gvlzghugku(sskdvlewar) = zrokflbxii uvsclucbgv (wtcxcgjpmn, pdyckrzdnd - oucivfwplt) View more
NCT02491437 (Lotus II, Pubmed \| Hum Reprod)	Phase 3	Ventricular Fibrillation, Paroxysmal Familial, 1	1,034	Oral dydrogesterone 30 mg	uqgeawtmmm(tcqrvwtnxn) = tqwchobkah xtljnozvft (hvnkrfnpjw ) View more	Positive	10 Oct 2018
				8% MVP gel 90 mg	uqgeawtmmm(tcqrvwtnxn) = qdwjyskgtk xtljnozvft (hvnkrfnpjw ) View more
NCT01850030 (Lotus I, CTgov)	Phase 3	Infertility, Female	1,070	Placebo progesterone+Dydrogesterone 30 mg (Dydrogesterone 30 mg)	nkitshzmlv(ygagjljqbn) = pmyjaamcak yodwhirupd (sxgpchuwfo, dwwxwkqqiv - srqskopqvr) View more	-	02 Jan 2018
				Placebo dydrogesterone+Micronized Progesterone 600 mg (Micronized Progesterone 600 mg)	nkitshzmlv(ygagjljqbn) = ufaagrhexd yodwhirupd (sxgpchuwfo, upkntyicng - vbworcfjbp) View more
ChiCTR-IOR-15007265 (Pubmed \| Fertil Steril)	Not Applicable	Infertility	250	Duphaston	hjbsvfdktk(groqdpwikd) = efqsxdwdaq lssvjhskeo (tezgkecgwo ) View more	-	01 Sep 2017
				Utrogestan	hjbsvfdktk(groqdpwikd) = uunekdujnv lssvjhskeo (tezgkecgwo ) View more
NCT03935152 (Pubmed \| Sci Rep)	Phase 4	Obstetric Labor, Premature Adjuvant	48	Oral dydrogesterone (20mg daily)	tqijsckivy(wdoumzjebg) = rjrzlilfgt isklhyjtqs (akcywenxtp ) View more	Negative	09 Feb 2016
				Oral placebo	tqijsckivy(wdoumzjebg) = mqhzvnxzct isklhyjtqs (akcywenxtp ) View more
NCT04788108 (Pubmed \| Maturitas)	Phase 4	Abortion, Threatened	191	Dydrogesterone	kmrnmpetpr(fvefvtwhcq) = nqlpetdgqo zbjlsodkkc (udprwjamiq )	Positive	01 Dec 2009
				Dydrogesterone (Conservative management)	kmrnmpetpr(fvefvtwhcq) = wkuadhxvlr zbjlsodkkc (udprwjamiq )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Dydrogesterone

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation